Gradalis Deploys L7’s Enterprise Science Platform for Next-generation Life Science Companies in Record Time to Support Mission-critical Immunotherapy Manufacturing and Clinical Trial Processes

Gradalis Deploys L7’s Enterprise Science Platform for Next-generation Life Science Companies in Record Time to Support Mission-critical Immunotherapy Manufacturing and Clinical Trial Processes

DALLAS, October 3, 2018 – Gradalis, Inc., a Dallas-based, clinical-stage, vertically-integrated immunotherapy company, announced today it has successfully implemented and launched L7’s Enterprise Science Platform (“ESP”). L7 Informatics, Inc., is the leading software...